Aktienanalyse zu VolitionRX Ltd (VNRX)VNRXVolitionRX Ltd

VolitionRx Limited is a company focused on advancing the science of epigenetics. The Company is focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its products are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

VolitionRX Ltd (VNRX) is currently trading at $0.1936, significantly below its 52-week high of $8.13, indicating potential for upside. However, the company has a troubling year-to-date change of -96.45% and a forward P/E ratio of 20.83, which suggests that while there is growth potential, it is not without risk. The recent partnership with Sysmex for optimizing diagnostic processes highlights a positive catalyst, but the company also reported a net income loss of -$7,326,047 in Q2 2026, which raises concerns about profitability. The RSI is at 52.60, indicating neutral momentum, and the stock is currently a penny stock, which adds to its volatility. The main risk is the high operating expenses that reached $6.3 million in Q1 2026, which could continue to pressure the company's financial health.

3 analysts cover VNRX: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 2.25.